The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC–IV Unresectable Ovarian Cancer
Authors:
- Laura MatteucciLMLaura Matteucci
- Stefano TamberiSTStefano Tamberi
- Valentina ArcangeliVAValentina Arcangeli
- Antonino DittoADAntonino Ditto
- Giuseppa MalteseGMGiuseppa Maltese
- Mauro SignorelliMSMauro Signorelli
- Fabio MartinelliFabio Martinelli
- Valentina ChiappaVCValentina Chiappa
- Umberto Leone Roberti MaggioreUMUmberto Leone Roberti Maggiore
- Stefania PerottoSPStefania Perotto
- Cono ScaffaCSCono Scaffa
- 1 November 2017
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (9) , 1856-1862
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European PerspectiveJournal of Clinical Oncology, 2017
- Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resectionGynecologic Oncology, 2017
- The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc–IV high-grade serous ovarian cancerArchives of Gynecology and Obstetrics, 2016
- Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?Oncology, 2016
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian CancerThe Oncologist, 2016
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialThe Lancet, 2015
- Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancerGynecologic Oncology, 2014
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000International Journal of Cancer, 2004